BIOMARIN PHARMACEUTICAL INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
BioMarin Pharmaceutical reported positive Phase 3 trial data for VOXZOGO in treating hypochondroplasia, supporting an FDA application. The data may expand VOXZOGO's market and impact BioMarin's growth strategy. Analysts project revenue of $5.0B and earnings of $1.3B by 2029, with a potential 41% upside. Risks include pricing pressure, competition, and high R&D costs.
BioMarin Pharmaceutical (BMRN) saw significant bullish options activity, with a 182:1 call-to-put ratio. A large call spread bet targets $100 by April 2027, indicating confidence in a 37% upside. Recent earnings beats and pipeline developments support this outlook, though competitive risks remain. Technical indicators also suggest strong momentum.
BioMarin Pharmaceutical Inc. (BMRN) appointed Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to its Board of Directors. Plenge brings extensive experience in drug discovery and pharmaceutical industry leadership. BioMarin focuses on developing medicines for rare genetic conditions.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning BMRN (BIOMARIN PHARMACEUTICAL INC). Coverage has skewed bullish: 4 bullish, 2 neutral, and 0 bearish.
Recent BMRN coverage spans financial news, technology and corporate actions.
In the last 30 days, BMRN insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($1.2M). The most active reporter was Davis George Eric, EVP, Chief Legal Officer, with 1 filing.
Positive trial data may boost expectations for VOXZOGO sales and expand the growth-disorder portfolio.
The large, fresh bull call spread suggests traders expect a significant upside move, potentially pushing the stock toward $100 by April 2027.
The board appointment adds a seasoned research leader, potentially strengthening BioMarin's pipeline and investor confidence.
Board expansion and RSU grant are routine governance actions with limited immediate price impact.
Settlement provides a royalty stream and removes litigation risk.
AlphAI scores every news story that mentions BMRN with an AI model for sentiment and relevance, and aggregates insider trades from BIOMARIN PHARMACEUTICAL INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
BioMarin Pharmaceutical reported positive Phase 3 trial data for VOXZOGO in treating hypochondroplasia, supporting an FDA application. The data may expand VOXZOGO's market and impact BioMarin's growth strategy. Analysts project revenue of $5.0B and earnings of $1.3B by 2029, with a potential 41% upside. Risks include pricing pressure, competition, and high R&D costs.
3 min readBioMarin Pharmaceutical (BMRN) saw significant bullish options activity, with a 182:1 call-to-put ratio. A large call spread bet targets $100 by April 2027, indicating confidence in a 37% upside. Recent earnings beats and pipeline developments support this outlook, though competitive risks remain. Technical indicators also suggest strong momentum.
2 min readBioMarin Pharmaceutical Inc. (BMRN) appointed Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to its Board of Directors. Plenge brings extensive experience in drug discovery and pharmaceutical industry leadership. BioMarin focuses on developing medicines for rare genetic conditions.
2 min readBIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 10, 2026, the Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company) increased the size
1 min readBioMarin (BMRN) shares rose 5% after settling a global patent dispute with Ascendis (ASND) over Yuviwel, an achondroplasia drug. Ascendis will pay BioMarin royalties of 20% of US net sales and 18% internationally until 2030. The settlement resolves pending litigation, including a US ITC investigation. Both companies framed the outcome positively, highlighting long-term benefits and commercial flexibility.
2 min readBioMarin (BMRN) reported positive Phase 3 results for VOXZOGO in treating hypochondroplasia, showing significant improvements in growth metrics. The company submitted an sNDA to the FDA for this new indication, aiming for a 2027 launch. VOXZOGO is currently approved for achondroplasia.
2 min readBioMarin (BMRN) settled patents with Ascendis, gaining a non-exclusive global license and royalties for TransCon CNP. It also completed its acquisition of Alesta Therapeutics, now a subsidiary. Jefferies raised its price target for BMRN to $105.00.
1 min readBioMarin (BMRN) settled patent disputes with Ascendis (ASND) over achondroplasia treatments, agreeing to receive royalties on Yuviwel sales. Under the deal, BMRN will get 20% of U.S. sales and 18% in other regions until 2030. While this reduces competitive risk, Voxzogo's market share could still be pressured. Yuviwel generated €8M in Q2 2026, with further expansion planned. BMRN shares are up 13% YTD, trading at a P/S ratio of 3.06.
2 min readDavis George Eric (EVP, Chief Legal Officer) sold 17,557 shares of BIOMARIN PHARMACEUTICAL INC (BMRN) at $66.28 ($1.16M total) on 2026-09-02.
1 min readModerna's market value surged $45B after positive cancer vaccine data. Ultragenyx gained FDA approval for Genglycos, its first gene therapy. BioMarin acquired Alesta Therapeutics for $275M. AstraZeneca scrapped a Phase 3 lung cancer trial. Argenx reported positive Phase 3 data for Vyvgart. Capricor's CEO indicated FDA willingness to review updated cell therapy submission.
5 min read
